In a high-content screen of FDA-approved anticancer drugs, Wan and colleagues (45) identified MEK2-dependent micropinocytosis as a requirement for LF uptake of MDA-MB-231 breast cancer EVs. Here, MAP2K2 is linked to breast cancer.